| Bioactivity | Taltobulin (HTI-286), a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Taltobulin inhibits the polymerization of purified tubulin, disrupts microtubule organization in cells, and induces mitotic arrest, as well as apoptosis[1]. | ||||||||||||
| Invitro | Taltobulin (HTI-286; 0.2-7.3 nM; 3 days) inhibits the growth of 18 tumor cell lines (leukemia, ovarian, NSCLC, breast, colon, and melanoma cell lines) with an average IC50 of 2.5±2.1 nM and a median value of 1.7 nM[1]. Cell Proliferation Assay[1] Cell Line: | ||||||||||||
| Name | Taltobulin | ||||||||||||
| CAS | 228266-40-8 | ||||||||||||
| Formula | C27H43N3O4 | ||||||||||||
| Molar Mass | 473.65 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Taltobulin
CAS: 228266-40-8 F: C27H43N3O4 W: 473.65
Taltobulin (HTI-286), a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circum
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.